Wednesday , July 28 2021

GRP or KOVID-19? What are the main differences ©

Influenza and COVID-19 are contagious respiratory diseases caused by various viruses:

  • COVID-19 is caused by a coronavirus infection called SARS-CoV-2,
  • Influenza is caused by infection with influenza viruses.

Some of the symptoms of influenza and KOVID-19 are similar. For this reason, distinguishing between them based solely on symptoms is difficult and requires testing to confirm the diagnosis.
There is still a lot of unknown information about COVID-19 and the virus that causes it.
From the information available so far, KOVID-19 seems to spread more easily than the flu and causes more serious complications in some people. In the case of KOVID-19, it takes longer for symptoms to appear and people can be contagious longer.

signs and symptoms

Both KOVID-19 and the flu have a wide range of symptoms, mild or severe, and even life-threatening complications.

Common symptoms of KOVID-19 and influenza have in common:

  • Fever or fever / fever
  • Cough
  • Difficulty breathing
  • Fatigue • Sore throat
  • Coryza or stuffy nose
  • Muscle aches or pains in the body
  • Headache



Influenza viruses can cause mild to severe forms of the disease, with the symptoms listed above.


People with KOVID-19 have a wide range of reported symptoms – from mild to severe.

Other signs and symptoms of COVID-19 other than influenza: anorexia, nausea, vomiting, diarrhea, impaired mental status, recent onset of anosmia (loss of smell) or aeugia (loss of taste) in the absence of an identified cause.

How long after exposure and infection do the symptoms appear?

In both KOVID-19 and influenza, symptoms may appear one day after exposure to the virus.



Usually, the flu appears suddenly: 1-4 days after infection.


In KOVID-19, symptoms may appear 2-14 days after exposure to the virus – an average of 5-7 days.

How long can the virus spread?

In both KOVID-19 and influenza, the virus can spread at least one day before symptoms appear.


If a person has KOVID-19, it can be contagious for a longer period of time than if they had the flu.


Older children and adults with the flu appear to be most infectious in the first 3-4 days of illness, but many remain contagious for about 7 days.
Infants and people with weakened immune systems can be infected for even longer.


How long the virus that causes KOVID-19 can spread is still being investigated.

It is possible for people to spread the virus about 2 days before they show symptoms and remain contagious for at least 10 days after the signs or symptoms appear. If someone is asymptomatic or the symptoms disappear, he or she may remain infected for at least 10 days after a positive KOVID-19 test.

How it spreads Both KOVID-19 and the flu can be spread from person to person, between people who are in close contact with each other:

  • Respiratory, through secretion drops produced when the infected person sneezes or coughs
  • With close contact with the infected person (touch, handling)
  • By touching contaminated surfaces, unhygienic hands are worn on the mouth, nose or eyes.

Differences COVID-19 is more contagious in certain populations and age groups than influenza.

The virus that causes KOVID-19 can spread quickly and easily to many people and can lead to continuous spread among people as time goes on.

People at high risk of serious illness.

Both KOVID-19 and the flu can lead to severe illness and complications.

The people most at risk are:

Most people get the flu the day before they show symptoms.

  • the elderly
  • People with certain comorbidities
  • Pregnant women


The risk of complications in healthy children is higher for influenza compared to KOVID-19.
Infants and children with basic medical conditions are at increased risk for both influenza and KOVID-19.


Young children have a higher risk of serious illness caused by the flu.


School-age children infected with KOVID-19 have a higher risk of multisystem inflammatory syndrome in children (MIS-C), a rare but severe complication of KOVID-19


Both KOVID-19 and influenza can lead to complications, including:

  • Pneumonia
  • Respiratory failure
  • Acute respiratory distress syndrome (i.e., fluid in the lungs)
  • septicemia
  • Heart damage (eg heart attack and stroke)
  • Multiple organ failure (respiratory failure, renal failure, shock)
  • Exacerbation of chronic medical conditions (including lung, heart, nervous system, or diabetes)
  • Inflammation of the heart, brain or muscle tissue
  • Secondary bacterial infections (ie infections that occur in people who have already been infected with influenza or KOVID-19)



Recovery from the flu can take from a few days to a maximum of two weeks. Some people may develop the complications listed above.


Additional complications associated with COVID-19 may include:

  • Blood clots in the veins and arteries of the lungs, heart, feet or brain
  • Multisystem Inflammatory Syndrome in Children (MIS-C)

Recovery from KOVID-19 can take 2-4 weeks.

Approved treatments

People at high risk for complications or who have been hospitalized for KOVID-19 or the flu should receive supportive care to help relieve symptoms and complications.



The flu can be treated with prescription antiviral drugs.


The protocol for treatment of infection with Kovid-19 was revised, upon the proposal of the Commission for Infectious Diseases of the Ministry of Health, with the support of the scientific commission KOVID-19 of the Ministry.

Basic recommendations:

  • A person with asymptomatic SARS-KOV-2 infection does not need drug treatment.
  • Patient follow-up is extremely important, the aggravation of suffering requires changes in therapeutic attitudes associated with the different therapeutic classes used.
  • Collaboration between physicians of different medical specialties is necessary in order to take care of the different / complex manifestations of COVID-19.
  • Antiviral drugs are more effective because they are administered earlier in the illness, preferably within the first 7-10 days; therefore antiviral drugs are recommended primarily in mild to moderate forms of the disease.
  • Among the available antiviruses, remedisivir is recommended only in medium or heavy forms (severe / critical forms), based on the criteria of availability, efficacy and risks.

These recommendations are periodically reviewed in the light of generally accepted scientific information from medical forums.

The vaccine


Vaccine manufacturers and other researchers and manufacturers are currently accelerating vaccine development to prevent KOVID-19. Any vaccine that reaches the EU market before it is available for purchase and use will have to meet all the scientific criteria for safety, efficacy and quality. If serious side effects are detected, the vaccine will not be available for use in the EU.


There are several flu vaccines that are produced annually to protect against the 3 or 4 types of flu viruses that are expected to circulate each year.

Influenza vaccination every year is the most effective preventive measure against seasonal flu.

Vaccination should ideally be carried out every year from mid-autumn. Depending on the type of virus circulating each year, the flu season lasts from October to May.

On December 3, as part of the flu immunization program for the 2020-2021 season, the Neam Public Health Directorate received a new tranche of influenza vaccine – 12,800 doses of flu vaccine tetra.

For the 2020-2021 epidemic season, PCT Neam requested 101,241 doses of influenza vaccine, of which 80,070 doses were administered. There are 40,078 doses in stock, at family doctors and at PCT Neamț.

39,992 doses were administered. No adverse reactions were reported after vaccination.



Source link